Maze Therapeutics (NASDAQ:MAZE) Shares Down 8.4% – Here’s Why

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s share price traded down 8.4% on Friday . The stock traded as low as $29.83 and last traded at $29.7010. 55,415 shares traded hands during trading, a decline of 92% from the average session volume of 712,930 shares. The stock had previously closed at $32.42.

Analyst Ratings Changes

Several equities research analysts have commented on MAZE shares. JPMorgan Chase & Co. increased their price objective on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, March 31st. BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, HC Wainwright lifted their price target on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Stock Down 8.1%

The stock has a 50-day moving average of $26.53 and a 200-day moving average of $35.39. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The company has a market cap of $1.65 billion, a PE ratio of -11.71 and a beta of 2.14.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million during the quarter. Sell-side analysts predict that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total transaction of $190,275.00. Following the completion of the sale, the insider directly owned 10,503 shares in the company, valued at $266,461.11. This represents a 41.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total value of $1,034,339.98. Following the completion of the transaction, the chief executive officer owned 23,337 shares in the company, valued at approximately $699,643.26. This represents a 59.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 141,470 shares of company stock worth $3,887,939 in the last 90 days. 5.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds have recently modified their holdings of MAZE. Seven Fleet Capital Management LP bought a new stake in shares of Maze Therapeutics in the first quarter worth about $917,000. Bank of America Corp DE lifted its holdings in Maze Therapeutics by 961.3% in the 1st quarter. Bank of America Corp DE now owns 195,084 shares of the company’s stock worth $5,823,000 after buying an additional 176,703 shares during the period. Royal Bank of Canada grew its position in shares of Maze Therapeutics by 214.1% in the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after buying an additional 1,383 shares during the last quarter. Exome Asset Management LLC bought a new stake in shares of Maze Therapeutics in the 1st quarter worth approximately $2,642,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Maze Therapeutics by 111.3% during the first quarter. The Manufacturers Life Insurance Company now owns 14,570 shares of the company’s stock valued at $435,000 after buying an additional 7,673 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.